The overall objective of this proposal is to use the current understanding of host defenses against schistosomiasis and of the biochemistry and molecular biology of the causative organisms to develop immunologic alternatives to control. Such an effort is needed because of the global prevalence of infection and the burden of illness in human population infected with several species of schistosomes. In spite of the recently developed anti-schistosome drugs, their long term effect and the danger of drug resistance may become a limiting factor in their usefulness as control measures. The target organism is a formidable immunologic challenge but recent evidence from our laboratory and others indicate that monoclonal antibodies and purified parasite antigens are capable of inducing significant resistance in experimental animals. Furthermore, the expanding science and technology of vaccine development and delivery offer new unique opportunities. We therefore propose to use the knowledge of host protective responses, its mechanisms and the increasingly expanding molecular understanding of schistosomes in order to isolate and characterize parasite antigens that can be tested as candidate vaccines.
The specific aims of this proposal are: 1. Biochemical characterization and cloning of protective antigens. 2. Selection of candidate subunit peptides for vaccines development. 3. Determination of optimal vaccination strategies. 4. Evaluation of human response to candidate vaccines. The proposal is designed as a series of step by step studies by using first immunoaffinity and biochemical procedures to purify two candidate antigens (SmW68 and SmW43) that have been identified by protective monoclonal antibodies. This will be followed by HPLC repurification using reverse phase hydrophobic interaction or ion exchange columns. Components peptides for amino acid sequence analysis will be generated from deglycosylate antigens by limited tryptic digestion. The larger peptides with single N- terminal will then be sequenced. Isolation of corresponding cDNAs from expression libraries will be achieved either by immunologic screening or by using oligonucleotide probes. Once defined peptide sequence are identified, we will use a combination of immunologic and biochemical procedures to delineate immunogenic epitopes and their effectiveness in inducing resistance in mice to be challenged percutaneously with S. mansoni. A major goal is to test these candidate vaccines for lack of sensitization to the immunopathological sequelae of schistosomiasis. Optimal vaccination strategies with stimulation of specific components of the host immune response or with clinically acceptable adjuvants will be determined. In addition, sera and peripheral mononuclear cells from individuals infected with S. mansoni will be examined for antibodies and sensitized T cells to candidate vaccine individuals infected with S. mansoni will be examined for antibodies and sensitized T cells to candidate vaccine antigens. We will also examine the in vivo human response to vaccination using the SCID-hu mouse model. Results obtained from these studies should pave the way to defining candidates for anti-schistosome vaccine.

Project Start
Project End
Budget Start
Budget End
Support Year
12
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Satayathum, Sudtida A; Muchiri, Eric M; Ouma, John H et al. (2006) Factors affecting infection or reinfection with Schistosoma haematobium in coastal Kenya: survival analysis during a nine-year, school-based treatment program. Am J Trop Med Hyg 75:83-92
King, Charles H (2006) Long-term outcomes of school-based treatment for control of urinary schistosomiasis: a review of experience in Coast Province, Kenya. Mem Inst Oswaldo Cruz 101 Suppl 1:299-306
Kim, Mikyung; Qiao, Zhi-Song; Montefiori, David C et al. (2005) Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. AIDS Res Hum Retroviruses 21:58-67
Liao, Hua-Xin; Alam, S Munir; Mascola, John R et al. (2004) Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins. J Virol 78:5270-8
Long, Timothy E (2003) Recent progress toward the clinical development of new anti-MRSA antibiotics. IDrugs 6:351-9
Li, Z; King, C L; Ogundipe, J O et al. (1995) Preferential recognition by human IgE and IgG4 of a species-specific Schistosoma haematobium serine protease inhibitor. J Infect Dis 171:416-22
Pearlman, E; Heinzel, F P; Hazlett Jr, F E et al. (1995) IL-12 modulation of T helper responses to the filarial helminth, Brugia malayi. J Immunol 154:4658-64
King, C L; Hakimi, J; Shata, M T et al. (1995) IL-12 regulation of parasite antigen-driven IgE production in human helminth infections. J Immunol 155:454-61
King, C L; Stupi, R J; Craighead, N et al. (1995) CD28 activation promotes Th2 subset differentiation by human CD4+ cells. Eur J Immunol 25:587-95
Mawhorter, S D; Kazura, J W; Boom, W H (1994) Human eosinophils as antigen-presenting cells: relative efficiency for superantigen- and antigen-induced CD4+ T-cell proliferation. Immunology 81:584-91

Showing the most recent 10 out of 77 publications